Pharmaceutical companies are accelerating their use of cloud infrastructure, automation, and artificial intelligence to support research, improve productivity, and move complex work through the organization more quickly. These investments are reshaping drug discovery, clinical operations, regulatory review, manufacturing coordination, and collaboration with external partners. As the operating model becomes more connected, the security model must also evolve. Protecting data inside the organization is no longer enough when sensitive information routinely moves across company boundaries.
That creates a practical question for pharmaceutical security leaders: who controls the certificate infrastructure behind encrypted external communication? The answer matters because pharmaceutical organizations exchange intellectual property, clinical documentation, legal materials, supplier information, and regulated records with third parties every day. Email remains one of the most common channels for these exchanges, even as collaboration platforms and specialized portals become more widely used. If the infrastructure securing those communications remains fragmented or heavily manual, it can become a weak point in an otherwise modern technology environment.
The Risk Begins When Information Leaves the Organization
Pharmaceutical companies have spent years strengthening internal defenses. Identity controls, endpoint protection, network monitoring, cloud-security tooling, and data-governance programs are all central parts of the modern security stack. These systems help reduce risk within the enterprise, but they do not fully address what happens when a document, message, or attachment is sent to an external recipient.
The external communication layer is more difficult to govern because recipients do not all use the same systems. A research partner may have its own security architecture. A supplier may rely on a different email environment. A law firm, regulator, clinical partner, or distribution network may have a separate set of technical capabilities and internal policies. The pharmaceutical company still needs to protect the information, even when the recipient sits outside its immediate control.
This is where secure email becomes more than a narrow messaging issue. A clinical document shared with the wrong recipient, an unprotected attachment sent under time pressure, or a confidential file moved into an unapproved collaboration channel can create material risk. The security architecture therefore needs to protect the message in a way that works consistently across different recipient environments, without forcing users to become experts in encryption workflows.
Why S/MIME Remains Relevant
S/MIME, or Secure/Multipurpose Internet Mail Extensions, remains one of the established standards for encrypting and digitally signing email. It allows organizations to protect message content and verify sender identity through digital certificates. In regulated sectors, that combination remains useful because it supports confidentiality while also creating a stronger basis for trust.
For pharmaceutical organizations, S/MIME can support a range of external communication scenarios. Research teams may need to exchange sensitive information with partners. Legal departments may need to send confidential materials to outside counsel. Regulatory affairs teams may share documentation with public authorities. Manufacturing and supply-chain teams may exchange operational information with vendors and contract partners.
The difficulty is not the encryption standard itself. The difficulty is operating it at scale. Certificates need to be issued, deployed, renewed, and revoked. They need to be associated with the correct identities. They need to continue working when employees change roles, devices are replaced, aliases are added, or business units are reorganized.
In a global pharmaceutical company, those events are routine. Teams are distributed across countries, programs begin and end, contractors join for limited periods, and acquisitions introduce new domains and identity systems. If certificate management depends on manual intervention, the process becomes slower and less consistent as the organization grows.
Manual Certificate Workflows Create Hidden Drag
The most visible cost of manual certificate management is administrative effort. Security and messaging teams spend time processing requests, resolving renewal issues, handling exceptions, and troubleshooting failures that could have been prevented through automation. Over time, that support burden becomes part of the cost of maintaining the encryption environment.
The less visible cost is inconsistency. Some users receive certificates quickly, while others wait. Some renewals happen well before expiry, while others are addressed only after a failure. Some business units follow standard processes, while others develop informal workarounds because the official route feels too slow or difficult.
That inconsistency matters because secure communication needs to work at the moment a sensitive message is sent. A scientist exchanging information with a research partner cannot afford to wait for a certificate issue to be resolved. A regulatory team working toward a filing deadline cannot treat secure delivery as an optional extra. A legal team handling confidential material cannot accept a workflow that fails unpredictably.
When the secure path becomes unreliable, users tend to find another route. They may send an attachment without protection, use a consumer file-sharing tool, or shift the conversation into a channel that was never designed for the information involved. The resulting exposure is often not caused by carelessness. It is caused by friction.
Cloud Transformation Changes the Standard
Pharmaceutical companies are not adopting cloud platforms simply to reduce infrastructure costs. They are using cloud environments to support more ambitious operating models built around data, automation, and AI-enabled workflows. Research teams need scalable computing resources. Digital teams need flexible environments for experimentation. Business units want faster access to information and less dependence on manual processes.
This broader transformation changes the standard for communication security. A certificate-management model that once seemed acceptable can become a bottleneck when the rest of the enterprise is moving faster. If cloud resources can be provisioned quickly, documents can be reviewed more efficiently, and workflows can be automated across departments, security controls around external communication also need to keep pace.
The question is not whether pharmaceutical organizations should give up control in the name of speed. The stronger approach is to automate routine work while preserving governance. That requires a model in which certificate issuance remains under enterprise authority, but the associated lifecycle processes no longer depend on tickets, spreadsheets, or repeated specialist intervention.
A Customer-Managed Model for S/MIME Automation
Echoworx recently announced a capability for automated S/MIME certificate generation using an enterprise-managed Certificate Authority hosted in AWS Private CA. According to the company’s public announcement, Echoworx connects securely to the customer’s AWS environment to request certificates, retrieve signed certificates, and deploy them for boundary email encryption.
The customer retains control of the Certificate Authority and the certificate-issuance process. Echoworx provides automation and lifecycle support without owning or operating the CA. For organizations that already use AWS strategically, the model creates a way to align secure external communication with a broader cloud architecture.
The significance lies in the balance between control and operational efficiency. A pharmaceutical company may want certificate issuance to remain under its own authority because the organization has strict governance requirements or internal policies around cryptographic infrastructure. At the same time, it may not want security teams to manage every request and renewal manually.
Customer-managed AWS Private CA environments provide a middle path. The organization keeps control of issuance, while automation reduces the burden on messaging and security teams. This makes S/MIME more practical across large and complex enterprises.
Why the Certificate Authority Matters
A Certificate Authority is not just a technical component sitting in the background. It is part of the trust model that supports encrypted and digitally signed communication. The CA issues the certificates that allow users and systems to establish confidence in the identities involved.
For regulated organizations, the governance question is straightforward. Who has authority to issue certificates? How are those certificates managed? How quickly can they be revoked? What evidence is available when an auditor, customer, or internal risk team asks how the process works?
A customer-managed CA can provide clearer answers. It gives the enterprise more direct authority over issuance and allows certificate policy to align with internal controls. When combined with automation, it also reduces the risk that lifecycle processes become dependent on manual administration.
This does not mean every pharmaceutical company needs the same architecture. Some organizations will continue to rely on external certificate providers. Others will prefer customer-managed environments. Many will use a combination of approaches depending on geography, business unit, or risk profile. The important point is that the choice should be deliberate and aligned with the organization’s operating model.
AI Increases the Pressure on Security Operations
Artificial intelligence is adding urgency to the discussion because it increases the speed and volume of digital work. AI-assisted tools can help teams analyze information, review documents, surface internal knowledge, and streamline complex workflows. These capabilities can create meaningful productivity gains, but they also place more pressure on the surrounding controls.
The issue is not that every AI-related output will be sent by email. The issue is that more information will move through the organization more quickly, and more decisions will be made in digitally accelerated environments. External communication systems need to support that pace without introducing friction or weakening governance.
A pharmaceutical company cannot build an AI-enabled operating model while leaving regulated communication dependent on brittle manual processes. Security needs to operate at the same speed as the business. That means certificate issuance, renewal, revocation, and deployment should be treated as infrastructure functions rather than administrative exceptions.
Regulation Is Raising Expectations
The regulatory environment reinforces the need for repeatable and auditable controls. The EU deadline for transposing NIS2 into national law passed on 17 October 2024, although national implementation timelines have varied. NIS2 broadens cybersecurity expectations across a wider range of organizations and places greater emphasis on governance, risk management, incident response, and resilience.
For pharmaceutical companies operating across Europe, the broader direction is clear. Security controls need to work consistently in practice, not only in policy documents. It is not enough to say that encryption is available. Organizations need to show that secure communication can be applied reliably across users, business units, and external interactions.
Certificate automation supports that goal because it reduces the number of manual exceptions in the system. It can help prevent expired certificates, delayed provisioning, inconsistent revocation, and avoidable service interruptions. It also gives security teams a stronger basis for explaining how encrypted communication fits into a wider governance framework.
The same pressure appears in procurement. Customers, partners, and public-sector bodies increasingly ask detailed questions about encryption, data protection, accessibility, hosting, resilience, and key management. Pharmaceutical companies need systems that can withstand that level of scrutiny.
External Communication Needs to Be Easy to Use
A technically strong system can still fail if users find it difficult to operate. Secure communication only works when employees and external recipients can use it without unnecessary complexity. That is why modernization should include the full communication journey rather than focusing only on the encryption layer.
Security leaders should examine how employees trigger encryption, whether policy can apply automatically, how recipients access protected messages, and whether the experience works consistently across desktop and mobile devices. They should also ask whether external recipients face unnecessary barriers and whether audit records are available when the organization needs them.
This matters because users rarely stop working when a security tool creates friction. They route around the obstacle. A better architecture reduces the temptation to create workarounds by making the protected path the easiest path to follow.
What Pharmaceutical Security Leaders Should Review
For CISOs, enterprise architects, and messaging leaders, the starting point is the operating model rather than the algorithm. The organization should understand who controls the CA, how certificates are issued, how renewals are handled, and how quickly credentials can be revoked. It should also know how many manual tickets are created each month, which business units experience the most friction, and where users are most likely to abandon the approved workflow.
The review should also examine the relationship between secure communication and the wider cloud strategy. If the enterprise has already standardized significant parts of its infrastructure around AWS, it should consider whether certificate management belongs inside that architecture. If the organization is trying to simplify its technology estate, it should identify whether legacy encryption systems are creating avoidable support costs or governance gaps.
The strongest architecture is not necessarily the one with the most features. It is the one that works consistently, produces evidence, and fits the way the organization actually operates.
Cloud Modernization Needs a Communication-Security Layer
Pharmaceutical companies are building faster, more connected, and more data-intensive operating models. Cloud platforms and AI are central to that shift, but modernization remains incomplete when sensitive external communication depends on outdated or heavily manual processes.
Email may not be the most visible part of the technology stack, but it remains one of the most persistent channels for formal business exchange. That makes it an important control point, particularly when intellectual property, patient-related information, legal materials, and regulated documents move outside the enterprise.
Customer-managed Certificate Authorities, automated S/MIME provisioning, and cloud-native lifecycle support offer a way to modernize that layer without weakening governance. For pharmaceutical companies, the value is practical: sensitive communication becomes easier to manage, more consistent to operate, and better aligned with the wider transformation already underway.
